The Impact of GLP1RA: Considerations for GI Physicians & Surgeons

March 20, 2024

AFS
Drs. Mike Ujiki, Carolyn Newberry, Manoel Galvao Neto, and Anthony Starpoli review GLP1RA. The panelists identify the current FDA-approved formulations on the market in the US and abroad. They define the current perioperative procedures regarding GLP1RAs in patients undergoing endoscopic or surgical procedures. Listen to the discussion on the current clinical practice in adding GLP1RAs to endoscopic bariatric procedures.
AFS, american foregut society, virtualed, glp1ra, glucagon-like peptide-1 receptor agonists, peptide1, glucagonlike, agonists, diabetes, obesity, dmii, dm2, diabetes mellitus, diabetes mellitus type 2, type 2, type2, weight, weight loss, weight management, weight loss medication, bmi, overweight, ozempic, wegovy, bariatrics, bariatric endoscopy, bariatric, GLP-1, GLP1, surgical endoscopy, gastroenterology, weight loss drug, weight loss drugs, glucagon, EBT, endoscopic bariatric therapy, Dr Ujiki, Dr. Ujiki, Dr. Mike Ujiki, Dr Mike Ujiki, Dr. Newberry, Dr Newberry, Dr. Carolyn Newberry, Dr Carolyn Newberry, Dr. Neto, Dr Neto, Dr. Manoel Galvao Neto, Dr Manoel Galvao Neto, Dr. Starpoli, Dr Starpoli, Dr. Anthony Starpoli, Dr Anthony Starpoli